Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Chromadex Corp CS (CDXC)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 186,789
  • Shares Outstanding, K 55,100
  • Annual Sales, $ 21,200 K
  • Annual Income, $ -11,380 K
  • 36-Month Beta 1.35
  • Price/Sales 8.86
  • Price/Cash Flow N/A
  • Price/Book 5.69

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -0.11
  • Number of Estimates 1
  • High Estimate -0.11
  • Low Estimate -0.11
  • Prior Year -0.17
  • Growth Rate Est. (year over year) +35.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.34 +1.50%
on 10/25/18
3.83 -11.49%
on 10/19/18
-0.26 (-7.12%)
since 10/12/18
3-Month
3.34 +1.50%
on 10/25/18
4.84 -29.96%
on 08/16/18
-1.41 (-29.38%)
since 08/14/18
52-Week
3.19 +6.27%
on 05/30/18
7.24 -53.18%
on 11/27/17
-2.56 (-43.03%)
since 11/14/17

Most Recent Stories

More News
ChromaDex (CDXC) Reports Q3 Loss, Misses Revenue Estimates

ChromaDex (CDXC) delivered earnings and revenue surprises of -33.33% and -9.78%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

CDXC : 3.39 (-0.59%)
ChromaDex Corporation Reports Third Quarter 2018 Financial Results

- Third Quarter 2018 Net Revenues Increased by 33% to $8.1 Million -

CDXC : 3.39 (-0.59%)
ChromaDex Appoints Matthew Roberts as Chief Scientific Officer and Senior Vice President of Innovation

ChromaDex Corp. (NASDAQ:CDXC) announced today that it has appointed Matthew Roberts as Chief Scientific Officer and Senior Vice President of Innovation, effective immediately.

CDXC : 3.39 (-0.59%)
Earnings Preview: ChromaDex (CDXC) Q3 Earnings Expected to Decline

ChromaDex (CDXC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CDXC : 3.39 (-0.59%)
ChromaDex to Report Third Quarter 2018 Financial Results on Wednesday, November 7, 2018

ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Wed., Nov. 7, 2018 at 4:30 p.m. Eastern time to discuss its financial results for the third quarter ended September 30, 2018....

CDXC : 3.39 (-0.59%)
TRU NIAGEN(R) Recognized as Best Product & Most Popular Brand at Health, Wellness & Beauty Awards 2018 of Watsons Hong Kong

TRU NIAGEN (nicotinamide riboside) receives best product award and recognized as top seller in 2018 amongst Watsons Hong Kong members

CDXC : 3.39 (-0.59%)
TRU NIAGEN(R) to be Featured at One-Day Medical School at Yale University School of Medicine

Inaugural event aims to empower women on critical health issues that arise after age 45

CDXC : 3.39 (-0.59%)
TRU NIAGEN(R) Daily Serving Strengthened Under FDA's NDI Notification

ChromaDex increases capsule serving to 150mg TRU NIAGEN(nicotinamide riboside), following successful New Dietary Ingredient (NDI) notification from FDA

CDXC : 3.39 (-0.59%)
Market Trends Toward New Normal in LSC Communications, Corindus Vascular Robotics, Sprouts Farmers Market, Luminex, ChromaDex, and CareDx -- Emerging Consolidated Expectations, Analyst Ratings

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of LSC Communications (NYSE:LKSD),...

LKSD : 10.34 (-1.05%)
CDXC : 3.39 (-0.59%)
LMNX : 25.94 (-1.52%)
CVRS : 1.18 (-2.48%)
SFM : 28.56 (+2.96%)
CDNA : 26.41 (+3.61%)
TRU NIAGEN(R) PRO to be Featured at the North American Menopause Society (NAMS) Annual Meeting

LOS ANGELES, Oct. 03, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) announced today that it will highlight its new TRU NIAGEN PRO product at the NAMS Annual Meeting 2018 in San Diego, CA, beginning...

CDXC : 3.39 (-0.59%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade CDXC with:

Business Summary

ChromaDex Corporation and its subsidiaries supply phytochemical reference standards and reference materials, related contract services, and products for the dietary supplement, nutraceutical, food and beverage, functional food, pharmaceutical and cosmetic markets. ChromaDex's core business strategy is...

See More

Key Turning Points

2nd Resistance Point 3.53
1st Resistance Point 3.46
Last Price 3.39
1st Support Level 3.35
2nd Support Level 3.31

See More

52-Week High 7.24
Fibonacci 61.8% 5.69
Fibonacci 50% 5.22
Fibonacci 38.2% 4.74
Last Price 3.39
52-Week Low 3.19

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar